Henan Zhonyuan Pharmaceutical Factory Gets New Lease Of Life
This article was originally published in PharmAsia News
Executive Summary
Henan Investment Group and Zhengzhou municipal government have signed an agreement to put up 490 million yuan to buy the Henan Zhongyuan Pharmaceutical factory. The plant could manufacture up to 5,000 tons of vitamin C, but due to facilities and approval issues, had ceased operations since 1996. The Zhengzhou government took on the debts of the beleaguered investors and paid off World Bank loans to reactivate the project. It has found Zhengzhou Tuoyang Industrial., a manufacturer of food additive E-Vc (sodium erythorbate), to lease a sizable floor space. Industry observers are divided on the success of reviving the factory. (Click here for more - Chinese Language)
You may also be interested in...
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.